Mr Dines is a Pharmacist with a MBA in Entrepreneurship/Finance. He is a former fortune 50 life science executive with a diverse background leading sales, business development, and product development with direct experience developing go to market, launching, and scaling national multi-billion-dollar growth opportunities.
Mr Dines was the first person to achieve orphan drug designation for a radiopharmaceutical in the USA, the product was launched by GE Healthcare.
Mr Dines, following a reorg, lead Walgreens Co's resurrection of the US 340B program. As the VP Health Systems he developed the strategy for the acquisition and retention of ambulatory prescriptions originating out of health systems. Notably, Mr Dines lead the transition of a stagnant 340B program from $10M/yr and fully repositioned, relauched, and scaled the program nationally generating $9.2B in annual revenues.
Mr Dines enjoys golf, skiing, and traveling with his wife, two girls! Boiler Up!
Mr Dines was the first person to achieve orphan drug designation for a radiopharmaceutical in the USA, the product was launched by GE Healthcare.
Mr Dines, following a reorg, lead Walgreens Co's resurrection of the US 340B program. As the VP Health Systems he developed the strategy for the acquisition and retention of ambulatory prescriptions originating out of health systems. Notably, Mr Dines lead the transition of a stagnant 340B program from $10M/yr and fully repositioned, relauched, and scaled the program nationally generating $9.2B in annual revenues.
Mr Dines enjoys golf, skiing, and traveling with his wife, two girls! Boiler Up!
Speaking In
[Available On-Demand]
OYE has repurposed and reformulated a injectable drug product that accelerates emergence from…